GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

Recent research throws into question whether GLP-1 drugs increase the risk of certain types of thyroid cancer.

Researchers assess whether GLP-1 receptor agonists increase the risk of suicide, self-harm, or suicidal ideation in type 2 ...

Ozempic and its ilk may do a lot of things, but raising the risk of suicide doesn’t appear to be one of them. Research out ...

Use of GLP-1 receptor agonists for obesity was associated with a reduced risk of primary open-angle glaucoma (POAG) and ...

A study presented at the 2025 Annual Meeting of the American Academy of Orthopaedic Surgeons examined the relationship between the patient's last dose of Ozempic, a common GLP-1, and ...

Doctors also might consider starting with lower doses of GLP-1 drugs and slowly increasing them for people with severe diabetes or a history of eye problems, he added. More research is needed to ...

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived longer, a new study shows.

“GLP-1 receptor agonist use was not associated with an increased risk of suicidal ideation, self-harm, or suicide” compared ...

Health experts are concerned Ozempic and other GLP-1 agonist drugs may be inappropriately prescribed to people experiencing disordered eating.

People taking the drugs had a lower risk of organ failure and death However, the drugs were associated with an increased risk ...